Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study

Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results

March 3, 2016 4:01 PM EST

ProTmune Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016

Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016

Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16

SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2015.

During this... More